2004Guoji yiyao weisheng daobaoRequires access

A Randomized and Double-blind Controlled Clinical Trial of Reboxetine for Treatment of Depression

李婷, 马崔

Open publisher page 0 citations

Abstract

目的 评价新药甲磺酸瑞波西汀治疗抑郁症的有效性和安全性.方法采用随机双盲双模拟、阳性药平行对照的研究.受试者分别口服瑞波西汀胶囊8mg/d或氟西汀片20mg/d.疗程6周.结果共收集符合入组条件的病人48例,两组各24例.主要疗效指标汉密尔顿抑郁量表(HAMD)评分在治疗结束时较基线显著减少(p<0.01).瑞波西汀组的有效率88%,氟西汀组的有效率100%,两组相比差异无显著意义.两组常见不良反应有口干、恶心、便秘、头昏、鼻塞、心电图异常等.两组间无显著性差异.结论试验药瑞波西汀与对照药氟西汀具有类似的疗效与不良反应,为治疗抑郁症的安全而有效的新药。

About this research paper

What this paper is about

目的 评价新药甲磺酸瑞波西汀治疗抑郁症的有效性和安全性.方法采用随机双盲双模拟、阳性药平行对照的研究.受试者分别口服瑞波西汀胶囊8mg/d或氟西汀片20mg/d.疗程6周.结果共收集符合入组条件的病人48例,两组各24例.主要疗效指标汉密尔顿抑郁量表(HAMD)评分在治疗结束时较基线显著减少(p<0.01).瑞波西汀组的有效率88%,氟西汀组的有效率100%,两组相比差异无显著意义.两组常见不良反应有口干、恶心、便秘、头昏、鼻塞、心电图异常等.两组间无显著性差异.结论试验药瑞波西汀与对照药氟西汀具有类似的疗效与不良反应,为治疗抑郁症的安全而有效的新药。

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

目的 评价新药甲磺酸瑞波西汀治疗抑郁症的有效性和安全性.方法采用随机双盲双模拟、阳性药平行对照的研究.受试者分别口服瑞波西汀胶囊8mg/d或氟西汀片20mg/d.疗程6周.结果共收集符合入组条件的病人48例,两组各24例.主要疗效指标汉密尔顿抑郁量表(HAMD)评分在治疗结束时较基线显著减少(p<0.01).瑞波西汀组的有效率88%,氟西汀组的有效率100%,两组相比差异无显著意义.两组常见不良反应有口干、恶心、便秘、头昏、鼻塞、心电图异常等.两组间无显著性差异.结论试验药瑞波西汀与对照药氟西汀具有类似的疗效与不良反应,为治疗抑郁症的安全而有效的新药。

Key concepts: Reboxetine, Double blind, Depression (economics), Single blind, Medicine, Randomized controlled trial, Internal medicine, Psychiatry

Related papers

Back to paper searchBrowse research topicsOriginal source
A Randomized and Double-blind Controlled Clinical Trial of Reboxetine for Treatment of Depression — Research Paper | ScholarLens